Journal article
Epidemiology, biology and therapy of Merkel cell carcinoma: conclusions from the EU project IMMOMEC
University Hospital Essen1
University of Michigan, Ann Arbor2
University Hospital Würzburg3
German Cancer Research Center4
Maastricht University Medical Center5
University Medical Center Hamburg-Eppendorf6
Dana-Farber Cancer Institute7
Peter McCallum Cancer Centre8
Section for Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark9
National Veterinary Institute, Technical University of Denmark10
University of Washington11
...and 1 moreMerkel cell carcinoma (MCC) is a highly aggressive, often lethal neuroendocrine cancer. Its carcinogenesis may be either caused by the clonal integration of the Merkel cell polyomavirus into the host genome or by UV-induced mutations. Notably, virally-encoded oncoproteins and UV-induced mutations affect comparable signaling pathways such as RB restriction of cell cycle progression or p53 inactivation.
Despite its low incidence, MCC recently received much attention based on its exquisite immunogenicity and the resulting major success of immune modulating therapies. Here, we summarize current knowledge on epidemiology, biology and therapy of MCC as conclusion of the project 'Immune Modulating strategies for treatment of Merkel Cell Carcinoma', which was funded over a 5-year period by the European Commission to investigate innovative immunotherapies for MCC.
Language: | English |
---|---|
Publisher: | Springer Berlin Heidelberg |
Year: | 2018 |
Pages: | 341-351 |
ISSN: | 14320851 and 03407004 |
Types: | Journal article |
DOI: | 10.1007/s00262-017-2099-3 |
ORCIDs: | 0000-0001-9183-653X |